Ollin Biosciences and Innovent Biologics have reported positive topline results from the randomized Phase 1b JADE trial, in which OLN324 (IBI324), a next-generation VEGF/Ang2 bispecific antibody, demonstrated superior anatomical efficacy over faricimab in patients with diabetic macular edema and wet age-related macular degeneration. Conducted in over 160 patients across the United States, the head-to-head study marks the first randomized trial to show a VEGF/Ang2 therapy outperforming faricimab on key clinical markers, including speed and magnitude of retinal drying.
Why OLN324’s anatomic gains matter in the high-bar setting of diabetic macular edema
The central finding from the JADE trial was a pronounced and early reduction in central subfield thickness in diabetic macular edema patients treated with OLN324. At Week 1, the mean reduction in CST reached 79 µm for the 4 mg OLN324 arm, compared to 45 µm in the faricimab group. This trend persisted at Week 12, where OLN324 achieved a 180 µm reduction versus 121 µm for faricimab. Clinicians familiar with the DME treatment landscape highlight that such early gains in retinal drying are often predictive of long-term disease control, potentially reducing both disease burden and injection frequency.
In addition, nearly 90 percent of OLN324-treated patients achieved full anatomical resolution of edema (defined as CST under 325 µm) by Week 12, compared to just 57 percent in the faricimab cohort. For a disease as refractory and chronic as DME, this scale of anatomical improvement in a short duration underscores the therapeutic potential of OLN324 as a disruptive entry in the $15 billion global retinal disease market.
What the JADE data suggests about wAMD differentiation and bispecific class durability
In wet age-related macular degeneration, OLN324 showed anatomical outcomes comparable to faricimab by Week 12, but numerical differences in best-corrected visual acuity gains favored the investigational drug. Although the study was not powered for statistical superiority in wAMD, the ability to match faricimab in structural outcomes while achieving slight edge in functional vision parameters may become more consequential in larger, upcoming Phase 3 programs.
The absence of significant inflammation signals in the OLN324 arms—alongside comparable or better efficacy—positions the molecule favorably within the bispecific class. Industry observers note that safety concerns, particularly intraocular inflammation and retinal vasculitis, have historically derailed several early-stage candidates in this space. The JADE trial reported no cases of intraocular inflammation among OLN324 patients, while one such case emerged in the faricimab group.
Why outperforming faricimab sets a new competitive benchmark for bispecifics
Since its launch, faricimab has functioned as the benchmark for dual VEGF-A and Ang2 inhibition. Its success stems not only from its dual mechanism but also from clinical data supporting extended dosing intervals. By directly comparing OLN324 to faricimab—and not to aflibercept or ranibizumab—Ollin and Innovent sought to test their asset against the most advanced competitor in the field.
The advantage reported by OLN324 was not only in terms of target engagement but also in its pharmacologic design. With up to 60-fold higher Ang2 potency and a smaller protein format, OLN324 delivers a higher molar dose per injection. Retinal specialists believe this pharmacological edge could potentially translate into better fluid control with less frequent dosing, a major unmet need in the DME population.
What the JADE trial reveals about trial design, real-world alignment, and next steps
The JADE study followed a straightforward, three-month loading design—administering three monthly injections and measuring primary outcomes at Week 12. This design aligns with real-world clinical practices and offers early insights into treatment durability. Patients were further assessed through Week 20, though longer-term outcomes have yet to be disclosed.
The design also allowed side-by-side assessment of 2 mg and 4 mg OLN324 doses, both of which showed comparable efficacy. This opens potential for dose optimization in future studies, possibly balancing efficacy, durability, and manufacturing costs. With favorable safety across both doses, OLN324 could be well positioned to serve as a flexible therapy tailored to disease severity or patient risk profiles.
Ollin Biosciences intends to advance the candidate into global Phase 3 trials for both diabetic macular edema and wet age-related macular degeneration, pending regulatory discussions. The full dataset is expected to be presented at the Angiogenesis, Exudation, and Degeneration 2026 symposium, a key venue for unveiling retinal drug development milestones.
What commercial and regulatory challenges still loom despite early promise
While the topline results from JADE are encouraging, the commercial path ahead for OLN324 will hinge on more than efficacy. Market incumbents such as faricimab, aflibercept, and ranibizumab have entrenched distribution channels and formulary access, particularly in the United States and Europe. Reimbursement decisions will require compelling comparative data that not only show better drying but also translate into lower treatment burden or longer dosing intervals.
Furthermore, with multiple biosimilars of aflibercept and ranibizumab entering the market, cost dynamics are shifting rapidly. OLN324 will need to navigate pricing pressures while justifying its premium with differentiated outcomes. Manufacturing scalability, particularly for a high-potency bispecific in a smaller protein format, will also be closely scrutinized by supply chain analysts and commercial leads.
From a regulatory perspective, the transition from Phase 1b to Phase 3 will require validation across larger, more diverse patient populations. Payers and regulators will likely expect confirmatory data that include durability, safety beyond 20 weeks, and functional vision gains across subgroups. Analysts suggest that if OLN324 can demonstrate extended durability with fewer injections over a 12-month window, its commercial value proposition would become much stronger.
What Innovent’s collaboration with Ollin reveals about emerging development models
The Innovent–Ollin partnership exemplifies a broader trend of cross-border co-development between discovery-led biotech firms in Asia and clinical execution specialists in the United States. Innovent, which discovered OLN324, brings deep biologics expertise and scalable antibody manufacturing infrastructure. Ollin, a relatively young company founded in 2023, provides U.S.-focused trial design, regulatory engagement, and commercial planning capabilities.
This split model—where discovery and early-stage work is handled in Asia, and late-stage execution is anchored in U.S. markets—is gaining traction in high-specialty segments such as ophthalmology, oncology, and autoimmune disease. If OLN324 succeeds in later-stage trials, the partnership may become a case study in cross-geographic biopharma collaboration tailored to therapeutic niches.
Why the OLN324–faricimab comparison could reset R&D priorities across the sector
The retinal therapeutics pipeline has been crowded with biosimilars, reformulations, and delivery innovations rather than mechanism-driven advances. OLN324’s early advantage in anatomic outcomes may rekindle interest in next-generation bispecifics targeting Ang2 and other vascular pathways. Biopharma companies that previously deprioritized Ang2 programs after mixed results may reconsider pipeline assets, especially in light of OLN324’s structure–activity enhancements.
Moreover, with real-world data showing gaps in treatment adherence and persistent disease activity even with monthly injections, therapies that promise faster resolution and more predictable responses could earn favor with both physicians and payers. The JADE study’s results, while early, introduce a credible challenger that could shift future investment from delivery convenience back toward molecular innovation.
Innovent–Ollin’s bispecific antibody OLN324 delivers superior retinal drying in DME added by Pallavi Madhiraju on
View all posts by Pallavi Madhiraju →